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BAG-1, a multifunctional protein, interacts with a plethora of cellular targets where the interaction
with HSC70 and HSP70, is considered vital. Structural studies have demonstrated the C-terminal of
BAG-1 forms a bundle of three alpha-helices of which helices 2 and 3 are directly involved in binding
to the chaperones. Here we found peptides derived from helices 2 and 3 of BAG-1 interfered with
BAG-1:HSC70 binding. We conﬁrmed that a 12 amino-acid peptide from helix 2 directly interacted
with HSC70 and when introduced into MCF-7 and ZR-75-1 cells, these peptides inhibited their
growth. In conclusion, we have identiﬁed a small domain within BAG-1 which appears to play a crit-
ical role in the interaction with HSC70.
Structured summary:
MINT-7265269, MINT-7265296, MINT-7265324, MINT-7265339, MINT-7265351, MINT-7265364, MINT-
7265483, MINT-7265464, MINT-7265310: HSC70 (uniprotkb:P11142) binds (MI:0407) to BAG1 (uni-
protkb:Q99933) by peptide array (MI:0081)
MINT-7265281: peptide 15L (uniprotkb:Q99933) binds (MI:0407) to HSC70 (uniprotkb:P11142) by surface
plasmon resonance (MI:0107)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
BAG-1 is a multifunctional protein that can modulate a wide
range of cellular processes [1]. For example, overexpression of
BAG-1 protects cells from a wide range of apoptotic stimuli, acti-
vates RAF-1 kinase-dependent signalling, enhances proliferation
and metastasis, regulates proteasomal degradation, and modulates
the transcriptional activity of a variety of nuclear hormone recep-
tors (NHR) [2–16]. Functional and expression studies suggest that
overexpression of BAG-1 may play an important role in diverse
cancer types [1,2,4,15,17–29].
The mechanism(s) by which BAG-1 exerts its pleiotropic effects
are not fully understood. Although BAG-1 has many protein bind-
ing partners (including BCL-2, RAF-1, pRb, CHIP and the protea-
some), interaction with the 70 kDa heat shock proteins, HSC70chemical Societies. Published by E
; HSC70, heat shock cognate
on resonance
s Division, Duthie Building,
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(P.A. Townsend).and HSP70, is considered key for many of BAG-1 functions
[5,14,28,30–33]. For example, mutations which prevent binding
to HSC70/HSP70 interfere with the ability of BAG-1 to promote cell
survival and to modulate NHR function [2,6,21,22,29,34–36]. In
addition, BAG-1 has been shown to modulate proteasomal degra-
dation of Tau proteins, a process dependent on the interaction with
HSC70/HSP70 [5]. Moreover, BAG-1 has cochaperone activity and
stimulates nucleotide exchange of HSC70/HSP70 [27,37–40]
HSC70 and HSP70 play important roles in multiple cell processes,
for example, via effects on protein (re)folding and activation of
NHR. Thus, binding to these multifunctional proteins may explain
at least in part the multiple effects associated with BAG-1
overexpression.
The interaction between BAG-1 and HSC70/HSP70 has been
studied by NMR and X-ray crystallography [34,41]. The 70 kDa
heat shock proteins comprise an amino terminal ATPase domain,
a central peptide binding domain and a carboxyl terminal region
that can form a ‘‘lid” over the peptide binding domain [42,43].
The interaction of BAG-1 with the ATPase domain of HSC70/
HSP70 is mediated by the C-terminal BAG domain of BAG-1. This
evolutionarily conserved ‘‘BAG domain” [44] is formed of a bundle
of three alpha-helices (Fig. 1). Helices 2 and 3 are involved in elec-lsevier B.V. All rights reserved.
Fig. 1. The BAG-1:HSC70 interaction. The ﬁgure shows the interaction between the
three helices comprising the BAG domain of BAG-1 (red) and the ATPase domain of
HSC70 (blue). The 8 amino-acid binding core of helix 2 (pink) and the 16 amino-acid
binding core of helix 3 (light blue) identiﬁed in this study are indicated. Figure was
drawn using PyMOL and structural coordinates from Protein Data Bank id 1hx1.
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main of HSC70 [41]. Although helix 1 is not directly involved in
binding, it may contribute to intramolecular interactions which
stabilize the overall structure of the BAG domain. In this paper,
we have identiﬁed small peptides derived from the BAG domain
that were sufﬁcient to inhibit the interaction of BAG-1 and
HSC70 and investigated their effect on breast cancer cell growth.
2. Materials and methods
2.1. BAG-1 peptides and GST-BAG-1
For in vitro studies, peptides were generated by solid phase syn-
thesis (Mimotopes Pty Ltd., Australia), dissolved in DMSO and
10 mM stock solutions stored at 80 C. For cell studies, Penetratin
[45] and Penetratin-coupled peptides were obtained from the Can-
cer Research UK Research Services (London, UK), dissolved in water
and 1 mM stocks stored at 80 C. The sequence of the Penetratin-







BAG-1 peptides were synthesised with Penetratin at their C-ter-
minus coupled via a peptide bond. The control peptide was an
unrelated BCL-2 derived sequence coupled to Penetratin by a disul-
phide bond at its N-terminus. GST and GST-BAG-1 were prepared
as previously described [46], and quantiﬁed using the BioRad pro-
tein assay and bovine serum albumin (BSA) as a standard. Number-
ing of amino-acid residues is from the human BAG-1 sequence.
2.2. BAG-1:HSC70 interaction assay
Wells of a 96 well tissue culture plate (Griener, UK) were coated
with 100 ng recombinant HSC70 (Stressgen Biotechnologies, USA)
in 100 ll phosphate buffered saline (PBS) at 4 C. The following
day, wells were washed three times in PBS and non-speciﬁc bind-
ing sites were blocked with PBS containing 0.1% (w/v) BSA (Sigma,UK) for 1 h at room temperature. The wells were washed as before,
prior to addition of GST-BAG-1S or GST (each 500 ng) in PBS. Fol-
lowing incubation at room temperature for 1.5 h, unbound protein
was removed by washing in PBS. Bound BAG-1 was detected using
the BAG-1-speciﬁc monoclonal antibody 3.10 G3E2 [46] at a 1/
1000 dilution of ascities in PBS (200 ll). Following incubation at
room temperature for 1 h, wells were washed and then incubated
for 1 h with 200 ll of horseradish peroxidase conjugated sheep
anti-mouse Ig antibody (GE/Amersham Biosciences, UK) diluted
in PBS (200 ll). Wells were washed and developed by addition of
200 ll of o-Phenylenediamine Dihydrochloride (Sigma, UK) and
incubation for 10 min at 37 C. Absorbance at 450 nm was deter-
mined on a Dynatech MR5000 plate reader (Dynatech, Germany).
The absorbance of wells containing HSC70 and GST was used to
determine the 0% interaction and the absorbance of wells contain-
ing HSC70 and GST-BAG-1S was used to determine the 100% inter-
action. Peptides were added to the interaction assay at various
concentrations prior to addition of GST-BAG-S.
2.3. Surface plasmon resonance (SPR)
SPR analysis was performed using BIAcore 2000 biosensor and
BIA evaluation 2.0 software (BIAcore, Sweden). CM5 carboxy-
methyl dextran sensor chips were activated with injection of
100 ll of a 1:1 mixture of N-ethyl-N0-[(dimethylamino)propyl]car-
bodiimide and N-hydroxysuccinimide. Immediately after activa-
tion, 30 ll of peptide 15L (100 lM) in HBS buffer (10 nM HEPES
with 0.15 M NaCl, 3.4 mM EDTA, and 0.005% surfactant P20; BIA-
core, Sweden) was injected for covalent coupling to the surface
of the sensor chip. Unreacted sites were blocked by injection of
70 ll of 1 M ethanolamine pH 8.5. Recombinant HSC70 was diluted
to the desired concentrations in HBS buffer and injected separately
over the chip-bound peptide 15L. Sensograms were collected at
25 C, with a ﬂow rate of 10 ll/min and data collection rate of
1 Hz. Sensograms were normalised to a base line of 0 resonance
units (RU). Equivalent concentrations of each protein were injected
over an untreated surface to serve as blank sensograms for subtrac-
tion of bulk refractive index background. The sensor chip surface
was regenerated between runs with a 1 min injection of 100 lM
HCl, at 10 ll/min.
2.4. Cell culture
ZR-75-1 and MCF-7 human breast cancer cell lines were ob-
tained from ATCC (American Type Culture Collection, USA) and
maintained in Dulbecco’s modiﬁed Eagle’s media (Life Technolo-
gies Inc., UK) supplemented with 10% (v/v) fetal calf serum (PAA
Laboratories, UK) and 1% (v/v) penicillin/streptomycin/glutamine.
To measure growth inhibition, cells were plated at a density of
5000 cells per well of a 96 well plate. The following day, cells were
treated with various concentrations of BAG-1 or control peptides.
After 6 days, media was removed from each well and replaced with
200 ll RPMI-1640 media (Life Technologies Inc., UK) supple-
mented with 10% (v/v) fetal calf serum and 1% (v/v) penicillin/
streptomycin/glutamine. CellTiter 96 AQueous One Solution Re-
agent (20 ll; Promega, UK) was added to the wells and the plate
incubated at 37 C for 1–4 h. Absorbance at 490 nm was measured
using a Dynatech MR 5000 plate reader.3. Results
3.1. Development of the in vitro BAG-1:HSC70 interaction assay
To investigate the ability of short peptides to disrupt the inter-
action between recombinant HSC70 and BAG-1S an in vitro inter-
Fig. 2. Development of the in vitro BAG-1:HSC70 interaction assay. The ﬁgure
shows the colorimetric reaction of the in vitro interaction between BAG-1 and
recombinant HSC70. The effects of varying concentrations of BAG-1 peptides are
shown in (a). Colorimetric reaction were selected peptides was measured and
normalized to controls (b).
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BAG-1 molecule interacting with HSC70 and assessed colorimetri-
cally. GST alone was used as a negative control (Fig. 2a). The effects
of varying concentrations of BAG-1 peptides on the BAG-1:HSC70
interaction was assessed (Fig. 2a). Levels of inhibition were mea-
sured by a colorimetric response and normalised to controls
(Fig. 2b).
3.2. Scanning peptides
To identify minimal domains of BAG-1 sufﬁcient to interact
with HSC70, we analysed the ability of a series of 29 overlapping
peptides derived from the BAG-1 C-terminus to disrupt the interac-
tion between HSC70 and BAG-1S. The peptides were all 20 amino-
acid residues in length and overlapped by 16 residues, except the
ﬁnal peptide which overlapped by 18 residues (Fig. 3). Peptides de-
rived from helix 1 of the BAG domain had no signiﬁcant effect on
the interaction of BAG-1 and HSC70 (Fig. 4). Although peptides
from helix 2 and 3 generally decreased the interaction to some ex-
tent, 6 peptides reproducibly inhibited interaction by >50% at
100 lM (peptides 12-15 from helix 2 and peptides 23 and 24 from
helix 3). These results are consistent with the known role of helices
2 and 3 in mediating interaction with HSC70 [34,47]. However,
since 4 contiguous peptides from helix 2 interfered with BAG-
1:HSC70 binding, these data suggest that a very small region com-
prising 8 amino-acid residues from helix 2 may be sufﬁcient to
bind HSC70. For helix 3, a larger region may be required to bind,
since only two overlapping peptides, sharing 16 residues, were
identiﬁed as strong inhibitors of binding. Dose response experi-ments were performed to determine EC50 values for some of these
peptides. The EC50 values for peptides 13 and 15 from helix 2 were
37 ± 19 lM and 25 ± 5 lM, respectively, and the EC50 value values
for peptides 23 and 24 from helix 3 were 30 ± 10 and 44 ± 5 lM,
respectively (all mean of two determinations ± S.D.).
3.3. Mutation analysis of helix 2 and 3 peptides
We generated a second set of peptides to more precisely deﬁne
regions required for inhibition of binding. Peptide 15 was selected
for this study, since the putative 8 residue ‘‘core” was located at the
N-terminus of this peptide (Fig. 5). Resynthesised peptide 15 (pep-
tide 15A) was less active than the original peptide, however, this is
likely to reﬂect differences in yield and purity of different prepara-
tions of peptides. Any deletions from the N-terminus resulted in a
signiﬁcant reduction in inhibitory activity (i.e. <50% inhibition at
100 lM). By contrast, deletions from the C-terminus were well tol-
erated until they approached the 8 amino-acid residue ‘‘core” re-
gion predicted from overlapping peptides (in peptide 15N).
Consistent with this, alanine substitutions were well tolerated
within the C-terminal half of the peptide, whereas alanine substi-
tutions in the ‘‘core” region were poorly tolerated. However, there
were some exceptions, for example, peptides 15Q and 15R retained
good inhibitory activity.
Similar deletion and substitution analysis was performed using
peptide 24 from helix 3 (Fig. 6). In this experiment, inhibition of
binding at a single concentration was analysed. Similar to peptide
15, any truncations from the N-terminus inactivated the peptide,
whereas C-terminal truncations were tolerated until a signiﬁcant
portion of the predicted core was lost (in 24I). Alanine substitu-
tions in the C-terminal portion of the peptide were tolerated
(24Q–T), whereas the effects of alanine substitutions in the N-ter-
minal were more variable. Alanine substitution of R237 and K238
in peptide 24K signiﬁcantly decreased the activity of the peptide,
whereas other alanine substitutions, such as Q245 in peptide
24O were tolerated.
3.4. Surface plasmon resonance (SPR)
Our data suggest that a relatively small peptide derived from
helix 2 is sufﬁcient to bind HSC70 and prevent interaction of intact
BAG-1 and HSC70. We performed SPR analysis to conﬁrm that he-
lix 2 peptide interacted directly with HSC70. Peptide 15L was
bound to the sensor chip and addition of recombinant HSC70 to
the ﬂow channel led to a concentration dependent increase in
the relative response. Removal of HSC70 from the buffer was
accompanied by a return to the base line showing that the interac-
tion between the peptide and HSC70 was fully reversible (Fig. 7).
These data demonstrate that peptide 15L interacted directly with
HSC70. Although we have not directly measured the kinetics of
binding, the binding and dissociation of HSC70 were relatively ra-
pid, consistent with the kinetics of the interaction of intact BAG-1
and HSC70 [48,49].
3.5. Effect of peptides on breast cancer cell growth
We determined the effects of the peptides on the growth of ZR-
75-1 and MCF-7 human breast cancer cell lines (Table 1). Since
peptides are poorly cell permeable, the peptides were coupled to
Penetratin, a cell permeable fragment of the Antennaepaedia pro-
tein that can act as a transporter to enhance cellular uptake [45].
Peptides H2-Pen (helix 2) and H3-Pen (helix 3) inhibited the
growth of breast cancer cells with EC50 concentrations of 25–
40 lM (Table 1). By contrast, control peptides (Penetratin peptide
alone or an unrelated peptide coupled to Penetratin) had no effect
on cell growth (EC50 > 100 lM). We also analysed the growth
Fig. 3. Overlapping peptides used to probe the BAG-1:HSC70 interaction. The top line shows the primary amino-acid sequence and the boundaries of the three alpha-helices
that comprise the BAG-1 C-terminal BAG domain. Below is shown the 29 overlapping peptides derived from this sequence.
Fig. 4. Inhibition of BAG-1:HSC70 binding by 29 overlapping peptides. The 29 peptides were tested for their ability to interfere with the BAG-1:HSC70 interaction at 100 lM.
The interaction of BAG-1 and HSC70 in the absence of peptide was used to set the 100% interaction level. Data shown are mean of three separate experiments each performed
in duplicate ± S.D.
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taining alanine substitutions at R205 and R206 which reduced
the ability of peptide 15 to interfere with BAG-1:HSC70 binding
(Fig. 5). H2mut-Pen inhibited cell growth with an EC50 of
55 lM and was therefore statistically signiﬁcantly less active
than peptide H2-Pen (P < 0.05, Student’s t-test using 6 individual
samples).
4. Discussion
The interaction of BAG-1 with HSC70 and HSP70 is thought to
be important for many of the functions of BAG-1 and may contrib-
ute to the activity of BAG-1 in malignant cells [1,50]. In this work,
we have identiﬁed small peptides derived from helices 2 and 3 of
the BAG-1 C-terminal BAG domain that prevent interaction of the
intact BAG-1 protein with HSC70. For helix 2, a relatively small
peptide of approx. ten amino-acid residues was sufﬁcient to bindHSC70. Therefore, although the overall size of the C-terminal do-
main of BAG-1 is 120 amino-acid residues, much smaller regions
from isolated alpha-helical regions are sufﬁcient to bind HSC70.
The two minimal binding domains identiﬁed in helix 2 and 3 are
juxtaposed to the HSC70 ATPase domain (Fig. 1). Peptides from he-
lix 1 had no inhibitory activity, consistent with the fact that this
helix is not directly involved in the interaction with HSC70.
NMR and X-ray crystallography studies have identiﬁed 13 ami-
no-acid residues in the BAG domain that are thought to be involved
in electrostatic interactions with the ATPase domain of HSC70
[34,41]. Seven of these amino-acid residues are in helix 2 and 4
are in helix 3, and 2 are in the loop between helix 2 and 3
(Fig. 8). Of the residues within helix 2, only R205 is contained in
the minimal binding domain from this helix, suggesting that
R205 plays a particularly important role in the interaction. How-
ever, it is likely that additional interactions are required for binding
of this peptide to HSC70, since some other alanine substitutions
Fig. 5. Mutational analysis of helix 2 peptide 15. The ﬁgure shows the sequence of
peptides derived from peptide 15, and EC50 values for inhibition of the BAG-
1:HSC70 interaction. Alanine substitutions are shown in bold and the predicted
‘‘core” sequences are indicated. Data are derived from a minimum of two (up to
four) separate experiments.
Fig. 6. Mutational analysis of helix 3 peptide 24. The ﬁgure shows the sequence of
peptides derived from peptide 24, and values for inhibition of the BAG-1:HSC70
interaction at 100 lM. Alanine substitutions are shown in bold and the predicted
‘‘core” sequences are indicated. Data are the mean interaction in the presence of
peptide (±S.D.) derived from 2 experiments each performed in duplicate. The
interaction of BAG-1 and HSC70 in the absence of peptide was used to set the 100%
interaction level.
Fig. 7. SPR analysis. Peptide 15L was coupled to the BIAcore CM5 sensor chip and
recombinant HSC70 introduced in to the ﬂow channel. The graph shows the
changes in resonance signal over time detected with 0 nM, 500 nM or 1 lM HSC70.
Experiment shown is representative of two similar experiments.
Table 1
Growth inhibition by BAG-1 peptides in breast cancer cell lines. EC50 for growth
inhibition (lM) is shown. Values are mean ± S.E. of the mean of three separate
experiments performed in duplicate.
Peptide ZR-75-1 MCF-7
H3-Pen 39.1 ± 3.6 37.2 ± 1.7
H2-Pen 26.7 ± 2.1* 39.9 ± 1.8*
H2mut-Pen 53.2 ± 3.0* 56.9 ± 0.7*
Con-Pen >100 >100
Penetratin >100 >100
* P < 0.05.
A. Sharp et al. / FEBS Letters 583 (2009) 3405–3411 3409also inactivated the peptide. Substitution at some positions was
tolerated and in general, these positions lie on the face of the al-
pha-helix that would be predicted to orientate away from HSC70.
Overall, the data suggest that R205 represents a ‘‘hot-spot” on
the interaction interface between BAG-1 and HSC70, and relatively
small peptides containing this region are particularly effective at
interfering with binding of intact BAG-1.
The minimal binding domain of helix 3 was larger, comprising
16 amino-acid residues. This domain contained all four of the res-
idues within helix 3 that were predicted to contribute electrostaticinteractions from structural studies [41] (Fig. 8). Overall, trunca-
tions and alanine substitutions of peptide 24 were more variable.
This suggests that multiple residues contribute signiﬁcant free en-
ergy to the interaction of BAG-1 helix 3 with HSC70.
Although the importance of HSC70/HSP70 binding for the func-
tion of overexpressed BAG-1 is well described, the signiﬁcance of
these interactions for endogenous BAG-1 is not known. We cou-
pled helix 2 and 3 derived peptides to Penetratin to facilitate cellu-
lar uptake and analysed their effects on cell growth of breast
cancer cells. Overexpression of BAG-1 in breast cancer has been
associated with outcome [21,51,52], so this is a relevant system
to study BAG-1 function. Both BAG-1 derived peptides inhibited
the growth of cells, whereas control peptides had no effect. A helix
2 peptide with alanine substitutions at R205 and R206 was signif-
icantly less active, consistent with these peptides acting via BAG-1/
HSC70. However, this peptide did retain some growth inhibitory
activity. This may relate to some retained afﬁnity for HSC70, or
possibly non-speciﬁc cytotoxic effects that have been observed
previously with alpha-helical peptides [53].
We postulate that these small peptides derived from the BAG
domain of BAG-1 exhibit their cellular effects by binding the ATP-
ase domain of HSC70 thus preventing the interaction between
BAG-1 and HSC70 (Fig. 9). BAG-1 has been shown to bind many
of its cellular targets via HSC70 and therefore disrupting this inter-
action may lead to a loss of BAG-1 function in breast cancer cells.
Moreover, we have recently shown that small molecules which
disrupt BAG-1 C-terminal protein:protein interactions inhibit the
growth of breast cancer cells and diminish BAG-1 function in cells
[54]. In the current study, we have interrogated the BAG-1 C-termi-
nal further and have demonstrated that short peptides derived
from the BAG domain of BAG-1 bind to the ATPase domain of
HSC70 and prevent the direct binding of BAG-1. This interaction
is critical for a variety of the functions attributed to BAG-1 in breast
Fig. 8. Structure of the BAG-1 HSC70 binding interface. The structure of the BAG-1 C-terminal domain viewed from the position of HSC70 in the BAG-1:HSC70 complex.
Figures were drawn using PyMOL and coordinates from PDB id 1hx1. The position of the 3 alpha helices are shown. (a) The position of the minimal binding domains is
indicated. (b) All BAG residues predicted to be involved in electrostatic interactions with HSC70 are shown in blue [41].
Fig. 9. Potential mechanisms for the biological effects of BAG-1 peptides. BAG-1 is a multifunctional protein that interacts with multiple cellular targets and modulates a wide
range of cellular processes (a) [1]. The C-terminal BAG domain of BAG-1 (red) has been shown to interact with the ATPase domain (blue) of the heat shock chaperone
molecule, HSC70 [34,41]. This interaction has been shown to be critical for the interaction between BAG-1 and many of its cellular targets, and may in part, explain the
multiple effects associated with BAG-1 [21,29]. Small molecules that block these protein:protein interactions mediated by the BAG domain have been shown to inhibit the
growth of breast cancer cells [54]. Consistent with this, we have shown that small peptides derived from the BAG domain of BAG-1 both block the interaction between BAG-1
and HSC70, and inhibit the growth of breast cancer cells. We hypothesise that small peptides (white) derived from the BAG domain of BAG-1 bind to the ATPase domain (blue)
of HSC70 preventing the binding of BAG-1 (b). This in turn prevents BAG-1 interacting with many of its cellular targets for which it requires binding to the heat shock
chaperone molecules. Therefore it is conceivable that small peptides that block the interaction between BAG-1 and HSC70 will decrease the activity of BAG-1 in breast cancer
cell lines. Figures were drawn using PyMOL and structural coordinates from Protein Data Bank id 1hx1.
3410 A. Sharp et al. / FEBS Letters 583 (2009) 3405–3411cancer cells [21,22,29]. Consistent with this, disruption of the
interaction may lead to a loss of BAG-1 function in breast cancer
cells (Fig. 9).
In this current study we have identiﬁed minimal HSC70 binding
domains located within the BAG-1 C-terminal domain and demon-
strated that relatively small peptides are sufﬁcient to interact with
HSC70. Thus, the BAG-1:HSC70 interaction may be an attractive
target for novel anti-cancer therapies aimed at inactivating this
multifunctional protein. Despite the difﬁculty in developing drugs
to target protein:protein interactions, the identiﬁcation of rela-
tively small active peptides and ‘‘hot-spots” within the BAG-1:HSC70-binding interface suggests, as demonstrated in by our re-
cent small molecules investigations, that it may be possible to
identify small chemical inhibitors of the BAG-1:HSC70 interaction
[54].
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